Key Takeaways
- • Invesque Inc. (TSX: IVQ, IVQ.U) has entered into an arrangement agreement for a go-private transaction with its controlling shareholder, a purchaser managed by Magnetar.
- • Minority shareholders are set to receive US$0.101 per share in cash, a premium of approximately 68% over the last closing price on September 29, according to the company's announcement.
- • Invesque, a North American health care real estate company, reported trailing-twelve-month revenue of US$13.64M and a net loss of US$37.67M, per Yahoo Finance data.
- • The stock traded near US$0.095 in early October, within a 52-week range of US$0.06 to US$0.115, implying a market capitalization of roughly US$86.8M.
Summary
Invesque Inc. has agreed to a go-private transaction with its controlling shareholder, under which a purchaser managed by Magnetar would acquire the company's publicly held shares. The company announced that it had entered into an arrangement agreement covering both its TSX-listed common shares (IVQ) and its U.S. dollar-denominated shares (IVQ.U). Minority shareholders are set to receive US$0.101 in cash per share, representing a premium of approximately 68% over the last closing price on September 29, according to the company's press release. Commentary on the deal has described it as a late-stage development in the company's strategic process, with a go-private outcome that would remove the public listing.
Invesque operates as a health care real estate company in North America. Its financial profile is weak on a trailing basis: revenue of US$13.64M against a net loss of US$37.67M, a return on equity of roughly -33%, and a profit margin of about -282%, according to Yahoo Finance. Total cash was reported at US$10.21M, and debt-to-equity stood at about 6.8%. The company has also previously announced its intention to redeem all US$27.3M in principal amount of outstanding debentures, a step tied to its capital structure rather than the go-private terms.
At the time of the Yahoo Finance snapshot, the shares traded at US$0.095 with a 52-week range of US$0.06 to US$0.115 and a beta of 1.18. The offer price of US$0.101 sits modestly above that level, which suggests the market was pricing the transaction close to its stated terms. Investors should review the arrangement agreement's conditions, including required approvals and any minority-protection mechanics, before drawing conclusions about the final consideration or timing.
Invesque operates as a health care real estate company in North America. Its financial profile is weak on a trailing basis: revenue of US$13.64M against a net loss of US$37.67M, a return on equity of roughly -33%, and a profit margin of about -282%, according to Yahoo Finance. Total cash was reported at US$10.21M, and debt-to-equity stood at about 6.8%. The company has also previously announced its intention to redeem all US$27.3M in principal amount of outstanding debentures, a step tied to its capital structure rather than the go-private terms.
At the time of the Yahoo Finance snapshot, the shares traded at US$0.095 with a 52-week range of US$0.06 to US$0.115 and a beta of 1.18. The offer price of US$0.101 sits modestly above that level, which suggests the market was pricing the transaction close to its stated terms. Investors should review the arrangement agreement's conditions, including required approvals and any minority-protection mechanics, before drawing conclusions about the final consideration or timing.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.